Richard L Tolman

This inventor holds 95 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents, primarily in Oligonucleotide Conjugates (CPC class 514284). Top assignees: Merck + Co., Inc., Geron Corporation, Icn Pharmaceuticals, Inc.. Active years: 1978-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard L Tolman. Retrieved from https://idiyas.com/inventor/richard-l-tolman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 95

% Patents Active = 95.8

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3

Average Co-Inventor Count = 3.2

ph-index = 23

Forward Citations = 1,472(Granted Patents)

Forward Citations (Not Self Cited) = 1,420(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Berkley Heights, NJ (US) (1978 - 1979)
Berkeley Heights, NJ (US) (1980)
Warren, NJ (US) (1981 - 2001)
Los Altos, CA (US) (1999 - 2006)
Carson City, NV (US) (2009)
Incline Village, CA (US) (2015)
Incline Village, NV (US) (2013 - 2017)

Company Filing History:

Icn Pharmaceuticals, Inc.

patents

4. 1 out of 834,570

Other

patents

Years Active: 1978-2017

Loading Chart...

Areas of Expertise:

Oligonucleotide Conjugates

Telomerase Inhibitors

Antidiabetic Agents

4-Azasteroids

Arylthiazolidinedione Derivatives

Substituted Indole Compounds

Peptide Binding Inhibitors

Stereoselective Synthesis

Benzisoxazole Compounds

Cholanic Acid Derivatives

Prodrugs

HIV Related Peptides

95 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9572891 - Oligonucleotide conjugates (2017-02-21),

2. 9072790 - Oligonucleotide conjugates (2015-07-07),

3. 8440635 - Oligonucleotide conjugates (2013-05-14),

4. 7563618 - Oligonucleotide conjugates (2009-07-21),

5. RE39056 - 4-Azasteroids for treatment of hyperandrogenic conditions (2006-04-03),

6. 6518268 - Telomerase inhibitors and methods of their use (2003-02-11),

7. 6515015 - Antidiabetic agents based on aryl and heteroarylacetic acids (2003-02-04),

8. 6452014 - Telomerase inhibitors and methods of their use (2002-09-17),

9. 6372742 - Substituted indole compounds and methods of their use (2002-04-16),

10. 6204273 - 16-substituted-4-aza-androstane 5-&agr;-reductase isozyme 1 inhibitors (2001-03-20),

11. 6200998 - Arylthiazolidinedione derivitives (2001-03-13),

12. 6160000 - Antidiabetic agents based on aryl and heteroarylacetic acids (2000-12-12),

13. 6143887 - Process for the stereoselective synthesis of (2000-11-07),

14. 6090839 - Antidiabetic agents (2000-07-18),

15. 6090836 - Benzisoxazole-derived antidiabetic compounds (2000-07-18),

Title: Richard L Tolman: A Trailblazer in Innovation and Patents

Introduction:

Throughout his illustrious career, Richard L Tolman has left an indelible mark on the field of technology and innovation. With key positions in prominent companies such as Merck & Company, Inc. and Geron Corporation, Tolman has played a pivotal role in driving advancements in various domains. This article delves into Tolman's remarkable achievements, his latest patents, notable collaborations, and the impact of his contributions.

Latest Patents:

Richard L Tolman's latest patents revolve around oligonucleotide conjugates. These innovative conjugates involve the covalent attachment of an oligonucleotide to an aromatic system. In specific embodiments, the oligonucleotide is designed to be complementary to the RNA component of human telomerase and is connected to a nucleobase through an optional linker. These groundbreaking conjugates effectively inhibit the activity of the telomerase enzyme, presenting promising prospects for combating telomerase-related diseases.

Career Highlights:

Throughout his career, Tolman has demonstrated immense expertise and leadership in the technology industry. Holding key positions in renowned companies, he has played a significant role in advancing innovation and driving strategic initiatives. His zeal for pushing boundaries and creating transformative solutions has led to numerous breakthroughs.

Collaborations:

Collaboration often fuels innovation, and Richard L Tolman is no stranger to successful partnerships. Notably, he has worked closely with Gary H Rasmusson and Soumya P Sahoo, both esteemed professionals in their respective fields. These collaborations have fostered synergistic efforts and unlocked new opportunities for developing groundbreaking technologies.

Conclusion:

Richard L Tolman's remarkable career and numerous accomplishments have solidified his status as a trailblazer in the realm of technology and innovation. His extensive patent portfolio, including the recent development of oligonucleotide conjugates, highlights his commitment to transformative solutions that push the boundaries of scientific understanding. As he continues to pave the way for future advancements, Tolman stands as an inspiration to aspiring innovators and inventors.

Please note: The information provided in this article is based on the given data, and any additional details about Richard L Tolman may not be available.

Profile summary based on public USPTO records.